These findings are raising the specter of using Tyrosine Kinase Inhibitors (TKI) in combination with anti-CD123 therapy in patients with high-risk CML. The gene discussed is IL3RA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.